Gitlab Inc vs 22nd Century Group Inc — how do they compare? Gitlab Inc trades at $31.79 (market cap $5.54B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Gitlab Inc is far larger — about 3644.7× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| GTLB | XXII | |
|---|---|---|
Market Cap | $5.54B | $1.52M |
Sector | Technology | Technology |
52-Week High | $51.04 | $1.47K |
52-Week Low | $19.42 | $3.90 |
Enterprise Value | $4.29B | -$6.71M |
Signals from Pluang's Aura AI — not financial advice
GitLab trades at $31.50, down 4.49% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $759.25M in 2025, though net income remained negative at -$6.33M. Recent earnings beats and a strategic position in AI-driven DevSecOps, including a fourth consecutive Gartner Magic Quadrant leadership recognition (Business Wire, 2026-06-17), highlight growth potential despite profitability challenges.
The outlook balances strong revenue growth and market position against high valuation multiples and persistent losses. Analyst consensus targets $32.50, suggesting modest upside, but risks include execution on profitability and competitive pressures in the software sector. Cash flow trends show improvement projected for 2026, yet investor caution is warranted given the elevated P/E ratio of 521.22.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →